المؤلفون: Hindi N; Medical Oncology Department, Fundacion Jimenez Diaz University Hospital and Hospital General de Villalba, Madrid; Instituto de Investigación Sanitaria-Fundación Jimenez Díaz-UAM (IIS-FJD-UAM), Madrid, Spain. Electronic address: nhindi@atbsarc.org., Razak A; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada., Rosenbaum E; Memorial Sloan Kettering Cancer Center, New York., Jonczak E; Department of Hematology Oncology, Miami University, Miami, USA., Hamacher R; Medical Oncology Department, West German Cancer Center, University Hospital Essen, Essen, Germany., Rutkowski P; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Bhadri VA; Medical Oncology Department, Chris O Brien Lifehouse, Sydney, Australia., Skryd A; Miller School of Medicine, University of Miami, Miami, USA., Brahmi M; Centre Leon Berard & University Claude Bernard Lyon 1, Lyon, France., Alshibany A; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada., Jagodzinska-Mucha P; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Bauer S; Medical Oncology Department, West German Cancer Center, University Hospital Essen, Essen, Germany., Connolly E; Medical Oncology Department, Chris O Brien Lifehouse, Sydney, Australia., Gelderblom H; Medical Oncology Department, Leiden University Medical Center, Leiden, The Netherlands., Boye K; Institute for Cancer Research, Oslo University Hospital, Oslo; Department of Oncology, Oslo University Hospital, Oslo, Norway., Henon C; Medical Oncology Department, Institut de Cancérologie Gustave Roussy, Villejuif, France., Bae S; Medical Oncology Department, Peter Mac Callum Center, Melbourne, Australia., Bogefors K; Department of Oncology, Skåne University Hospital and Lund University, Lund, Sweden., Vincenzi B; Medical Oncology Department, University Campus Bio-Medico, Rome, Italy., Martinez-Trufero J; Medical Oncology Department, Hospital Universitario Miguel Servet, Zaragoza., Lopez-Martin JA; Medical Oncology Department, Hospital Universitario 12 de Octubre, Translational Oncology Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid., Redondo A; Medical Oncology Department, Hospital Universitario La Paz-IdiPAZ, Madrid., Valverde C; Medical Oncology Department, Hospital Universitario Vall d'Hebron, Barcelona., Blay JY; Centre Leon Berard & University Claude Bernard Lyon 1, Lyon, France., Moura DS; Instituto de Investigación Sanitaria-Fundación Jimenez Díaz-UAM (IIS-FJD-UAM), Madrid, Spain., Gutierrez A; Hematology Department, Hospital Universitario Son Espases, Palma, Spain., Tap W; Memorial Sloan Kettering Cancer Center, New York., Martin-Broto J; Medical Oncology Department, Fundacion Jimenez Diaz University Hospital and Hospital General de Villalba, Madrid; Instituto de Investigación Sanitaria-Fundación Jimenez Díaz-UAM (IIS-FJD-UAM), Madrid, Spain.

المصدر: ESMO open [ESMO Open] 2023 Dec; Vol. 8 (6), pp. 102045. Date of Electronic Publication: 2023 Nov 27.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 101690685 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2059-7029 (Electronic) Linking ISSN: 20597029 NLM ISO Abbreviation: ESMO Open Subsets: MEDLINE

مواضيع طبية MeSH: Sarcoma, Alveolar Soft Part*/drug therapy , Sarcoma, Alveolar Soft Part*/pathology , Antineoplastic Agents*/therapeutic use, Adult ; Humans ; Child, Preschool ; Child ; Adolescent ; Young Adult ; Middle Aged ; Immune Checkpoint Inhibitors/pharmacology ; Immune Checkpoint Inhibitors/therapeutic use ; Retrospective Studies ; Protein Kinase Inhibitors/therapeutic use

المؤلفون: Martin-Broto J; Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autonoma de Madrid (IIS-FJD, UAM), 28040, Madrid, Spain. jmartin@atbsarc.org.; Medical Oncology Department, Fundación Jimenez Diaz University Hospital, Av. de los Reyes Católicos, 2, 28040, Madrid, Spain. jmartin@atbsarc.org.; General de Villalba University Hospital, 28400, Madrid, Spain. jmartin@atbsarc.org., Valverde C; Medical Oncology department, Vall d'Hebron University Hospital, 08035, Barcelona, Spain., Hindi N; Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autonoma de Madrid (IIS-FJD, UAM), 28040, Madrid, Spain.; Medical Oncology Department, Fundación Jimenez Diaz University Hospital, Av. de los Reyes Católicos, 2, 28040, Madrid, Spain.; General de Villalba University Hospital, 28400, Madrid, Spain., Vincenzi B; Medical Oncology, University Campus Bio-Medico and Fondazione Policlinico Universitario Campus Bio-Medico, 00128, Rome, Italy., Martinez-Trufero J; Medical Oncology Department, University Hospital Miguel Servet, 50009, Zaragoza, Spain., Grignani G; Medical Oncology Unit, Città della Salute e della Scienza Hospital, 10126, Turin, Italy., Italiano A; Medical Oncology department, Institute Bergonié, 33076, Bordeaux, France., Lavernia J; Medical Oncology department, Fundación Instituto Valenciano de Oncologia, 46009, Valencia, Spain., Vallejo A; Pathology department, Hospital Regional Universitario de Malaga, 29010, Malaga, Spain., Tos PD; Department of Medicine, School of Medicine, University of Padua, 35122, Padua, Italy., Le Loarer F; Pathology department, Institute Bergonié, 33076, Bordeaux, France., Gonzalez-Campora R; Pathology department, Hospital Quironsalud, 14004, Cordoba, Cordoba, Spain., Ramos R; Pathology department, University Hospital Son Espases, 07120, Mallorca, Spain., Hernández-Jover D; Radiology department, Sant Pau University Hospital, 08025, Barcelona, Spain., Gutierrez A; Hematology department, University Hospital Son Espases, 07120, Mallorca, Spain., Serrano C; Medical Oncology department, Vall d'Hebron University Hospital, 08035, Barcelona, Spain., Monteagudo M; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Letón R; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Robledo M; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Institute of Health Carlos III (ISCIII), Madrid, Spain., Moura DS; Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autonoma de Madrid (IIS-FJD, UAM), 28040, Madrid, Spain., Martin-Ruiz M; Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autonoma de Madrid (IIS-FJD, UAM), 28040, Madrid, Spain., López-Guerrero JA; Molecular Biology department, Fundación Instituto Valenciano de Oncologia, 46009, Valencia, Spain., Cruz J; Pathology department, Fundación Instituto Valenciano de Oncologia, 46009, Valencia, Spain., Fernandez-Serra A; Molecular Biology department, Fundación Instituto Valenciano de Oncologia, 46009, Valencia, Spain., Blay JY; Medicine Department, Centre Léon Bérard, 69008, Lyon, France., Fumagalli E; Medicine Department, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133, Milan, Italy., Martinez-Marin V; Department of Medical Oncology, Hospital Universitario La Paz-IdiPAZ, P. Castellana, 261, 28046, Madrid, Spain.

المصدر: Molecular cancer [Mol Cancer] 2023 Aug 09; Vol. 22 (1), pp. 127. Date of Electronic Publication: 2023 Aug 09.

نوع المنشور: Clinical Trial, Phase II; Letter; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101147698 Publication Model: Electronic Cited Medium: Internet ISSN: 1476-4598 (Electronic) Linking ISSN: 14764598 NLM ISO Abbreviation: Mol Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents*/therapeutic use , Gastrointestinal Stromal Tumors*/drug therapy , Gastrointestinal Stromal Tumors*/genetics , Sarcoma*/drug therapy, Adult ; Humans ; Mutation ; Protein Kinase Inhibitors/therapeutic use ; Proto-Oncogene Proteins c-kit/genetics

المؤلفون: Sanz-Paris A; Department of Endocrinology and Nutrition, Miguel Servet Hospital, 50009 Zaragoza, Spain. asanzp@salud.aragon.es.; Instituto de Investigación Sanitaria Aragón (IIS Aragon), 50009 Zaragoza, Spain. asanzp@salud.aragon.es., Martinez-García M; Department of Endocrinology and Nutrition, Miguel Servet Hospital, 50009 Zaragoza, Spain., Martinez-Trufero J; Department of Oncology, Miguel Servet Hospital, 50009 Zaragoza, Spain., Lambea-Sorrosal J; Department of Oncology, University Clinic Hospital, 50009 Zaragoza, Spain., Calvo-Gracia F; Department of Endocrinology and Nutrition, University Clinic Hospital, 50009 Zaragoza, Spain., López-Alaminos ME; Department of Endocrinology and Nutrition, Miguel Servet Hospital, 50009 Zaragoza, Spain.

المصدر: Nutrients [Nutrients] 2019 Aug 13; Vol. 11 (8). Date of Electronic Publication: 2019 Aug 13.

نوع المنشور: Journal Article; Systematic Review

بيانات الدورية: Publisher: MDPI Publishing Country of Publication: Switzerland NLM ID: 101521595 Publication Model: Electronic Cited Medium: Internet ISSN: 2072-6643 (Electronic) Linking ISSN: 20726643 NLM ISO Abbreviation: Nutrients Subsets: MEDLINE

مواضيع طبية MeSH: Algorithms* , Clinical Protocols* , Food, Formulated*/adverse effects , Nutritional Status*, Antineoplastic Agents/*adverse effects , Diarrhea/*therapy , Enteral Nutrition/*methods , Malnutrition/*therapy , Radiation Injuries/*therapy, Diarrhea/chemically induced ; Diarrhea/physiopathology ; Enteral Nutrition/adverse effects ; Humans ; Intestinal Absorption ; Malnutrition/chemically induced ; Malnutrition/physiopathology ; Nutritive Value ; Organism Hydration Status ; Radiation Injuries/etiology ; Radiation Injuries/physiopathology ; Radiotherapy/adverse effects ; Risk Factors ; Treatment Outcome

المؤلفون: Judson I; The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK. Electronic address: Ian.Judson@icr.ac.uk., Morden JP; Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK., Kilburn L; Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK., Leahy M; The Christie NHS Foundation Trust, Manchester, UK., Benson C; The Royal Marsden NHS Foundation Trust, London, UK., Bhadri V; Chris O'Brien Lifehouse, Sydney, NSW, Australia., Campbell-Hewson Q; Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK., Cubedo R; Hospital Puerta de Hierro, Madrid, Spain., Dangoor A; University Hospitals Bristol NHS Foundation Trust, Bristol, UK., Fox L; Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK., Hennig I; Nottingham University Hospitals NHS Trust, Nottingham, UK., Jarman K; Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK., Joubert W; Princess Alexandra Hospital, Brisbane, QLD, Australia., Kernaghan S; Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK., López Pousa A; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., McNeil C; Chris O'Brien Lifehouse, Sydney, NSW, Australia., Seddon B; University College London Hospitals NHS Foundation Trust, London, UK., Snowdon C; Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK., Tattersall M; Chris O'Brien Lifehouse, Sydney, NSW, Australia., Toms C; Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK., Martinez Trufero J; Hospital Miguel Servet, Zaragoza, Spain., Bliss JM; Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK.

المصدر: The Lancet. Oncology [Lancet Oncol] 2019 Jul; Vol. 20 (7), pp. 1023-1034. Date of Electronic Publication: 2019 May 31.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents/*therapeutic use , Quinazolines/*therapeutic use , Sarcoma, Alveolar Soft Part/*drug therapy , Soft Tissue Neoplasms/*drug therapy, Adult ; Aged ; Double-Blind Method ; Female ; Humans ; Male ; Middle Aged ; Young Adult

المؤلفون: Martin-Broto J; Department of Medical Oncology, University Hospital Virgen del Rocío, Sevilla, Spain; Institute of Biomedicine of Sevilla, Sevilla, Spain. Electronic address: jmartin@mustbesevilla.org., Stacchiotti S; Adult Mesenchymal and Rare Tumor Unit, Department of Cancer Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Lopez-Pousa A; Department of Medical Oncology, Sant Pau Hospital, Barcelona, Spain., Redondo A; Department of Medical Oncology, University Hospital La Paz, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain., Bernabeu D; Musculoskeletal Imaging Section, University Hospital La Paz, Madrid, Spain., de Alava E; Department of Pathology, University Hospital Virgen del Rocío, Sevilla, Spain; Institute of Biomedicine of Sevilla, Sevilla, Spain; CIBERONC, Madrid, Spain., Casali PG; Adult Mesenchymal and Rare Tumor Unit, Department of Cancer Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Italiano A; Department of Oncology, Institut Bergonié, Bordeaux, France., Gutierrez A; Department of Hematology, University Hospital Son Espases, Palma, Balearic Islands, Spain., Moura DS; Institute of Biomedicine of Sevilla, Sevilla, Spain., Peña-Chilet M; Clinical Bioinformatics Area, Fundación Progreso y Salud, University Hospital Virgen del Rocío, Sevilla, Spain., Diaz-Martin J; Institute of Biomedicine of Sevilla, Sevilla, Spain., Biscuola M; Department of Pathology, University Hospital Virgen del Rocío, Sevilla, Spain; CIBERONC, Madrid, Spain., Taron M; Institute of Biomedicine of Sevilla, Sevilla, Spain., Collini P; Soft Tissue and Bone Pathology, Histopathology and Pediatric Pathology Unit, Department of Diagnostic Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Ranchere-Vince D; Department of Pathology, Centre Léon Bérard, Université Claude Bernard Lyon, Lyon, France., Garcia Del Muro X; Catalan Institute of Oncology, Barcelona, Spain; Institut d'Investigació Biomédica de Bellvitge, University of Barcelona, Barcelona, Spain., Grignani G; Sarcoma Unit, Division of Medical Oncology, Candiolo Cancer Institute, FPO, IRCCS, Candiolo, Italy., Dumont S; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France., Martinez-Trufero J; Department of Medical Oncology, University Hospital Miguel Servet, Zaragoza, Spain., Palmerini E; Chemotherapy Unit, Istituto Ortopedico Rizzoli, Bologna, Italy., Hindi N; Department of Medical Oncology, University Hospital Virgen del Rocío, Sevilla, Spain; Institute of Biomedicine of Sevilla, Sevilla, Spain., Sebio A; Department of Medical Oncology, Sant Pau Hospital, Barcelona, Spain., Dopazo J; Clinical Bioinformatics Area, Fundación Progreso y Salud, University Hospital Virgen del Rocío, Sevilla, Spain., Dei Tos AP; Department of Medicine, University of Padua School of Medicine, Padua, Italy., LeCesne A; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France., Blay JY; Department of Medical Oncology, Centre Léon Bérard, Université Claude Bernard Lyon, Lyon, France., Cruz J; Department of Medical Oncology, University Hospital of Canarias, Tenerife, Spain.

المصدر: The Lancet. Oncology [Lancet Oncol] 2019 Jan; Vol. 20 (1), pp. 134-144. Date of Electronic Publication: 2018 Dec 18.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Angiogenesis Inhibitors/*therapeutic use , Antineoplastic Agents/*therapeutic use , Pyrimidines/*therapeutic use , Soft Tissue Neoplasms/*drug therapy , Solitary Fibrous Tumors/*drug therapy , Sulfonamides/*therapeutic use, Adult ; Aged ; Angiogenesis Inhibitors/administration & dosage ; Angiogenesis Inhibitors/adverse effects ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Female ; Humans ; Indazoles ; Male ; Middle Aged ; Multivariate Analysis ; Pyrimidines/administration & dosage ; Pyrimidines/adverse effects ; Response Evaluation Criteria in Solid Tumors ; Soft Tissue Neoplasms/pathology ; Solitary Fibrous Tumors/pathology ; Sulfonamides/administration & dosage ; Sulfonamides/adverse effects ; Survival Analysis

المؤلفون: Rubió-Casadevall J; Department of Medical Oncology, Institut Català d'Oncologia de Girona, Hospital Josep Trueta, Girona, Spain, jrubio@iconcologia.net., Martinez-Trufero J, Garcia-Albeniz X, Calabuig S, Lopez-Pousa A, Del Muro JG, Fra J, Redondo A, Lainez N, Poveda A, Valverde C, De Juan A, Sevilla I, Casado A, Andres R, Cruz J, Martin-Broto J, Maurel J

مؤلفون مشاركون: Spanish Group for Research on Sarcoma (GEIS)

المصدر: Annals of surgical oncology [Ann Surg Oncol] 2015 Sep; Vol. 22 (9), pp. 2948-57. Date of Electronic Publication: 2015 Jan 22.

نوع المنشور: Journal Article; Multicenter Study

بيانات الدورية: Publisher: Springer Country of Publication: United States NLM ID: 9420840 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1534-4681 (Electronic) Linking ISSN: 10689265 NLM ISO Abbreviation: Ann Surg Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents/*therapeutic use , Gastrointestinal Stromal Tumors/*surgery , Imatinib Mesylate/*therapeutic use , Metastasectomy/*mortality , Neoplasm Recurrence, Local/*surgery, Combined Modality Therapy ; Female ; Follow-Up Studies ; Gastrointestinal Stromal Tumors/drug therapy ; Gastrointestinal Stromal Tumors/mortality ; Gastrointestinal Stromal Tumors/pathology ; Humans ; Male ; Middle Aged ; Neoplasm Metastasis ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/mortality ; Neoplasm Recurrence, Local/pathology ; Neoplasm Staging ; Prognosis ; Retrospective Studies ; Survival Rate

المؤلفون: Maurel J; Medical Oncology Service, University Hospital Miguel Servet, Av. Isabel La Catolica 1-3, Zaragoza, Spain., Martinez-Trufero J, Artal A, Martin C, Puertolas T, Zorrrilla M, Herrero A, Antón A, Rosell R

المصدر: Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2000 Nov; Vol. 30 (2), pp. 107-16.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8800805 Publication Model: Print Cited Medium: Print ISSN: 0169-5002 (Print) Linking ISSN: 01695002 NLM ISO Abbreviation: Lung Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents/*therapeutic use , Carcinoma, Non-Small-Cell Lung/*diagnosis , Lung Neoplasms/*diagnosis , Lymph Nodes/*pathology , Platinum Compounds/*therapeutic use, Adult ; Aged ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/mortality ; Carcinoma, Non-Small-Cell Lung/secondary ; Female ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/mortality ; Lung Neoplasms/pathology ; Male ; Mediastinum/pathology ; Middle Aged ; Prognosis ; Retrospective Studies ; Survival Analysis ; Treatment Outcome

المؤلفون: Joaquín Dopazo, Nadia Hindi, Herminia Pérez-Vega, Jose A. Lopez-Martin, Javier Martin-Broto, Irene Carrasco-Garcia, Paola Collini, Lorenzo D'Ambrosio, Antonio Gutierrez, Andrés Redondo, Giovanni Grignani, Enrique de Álava, Antonio Lopez-Pousa, Javier Martinez-Trufero, Silvia Stacchiotti, Maria Lopez-Alvarez, Claudia Valverde, Víctor Encinas-Tobajas, David S. Moura, Maria Peña-Chilet

المساهمون: Grupo GEIS, Pfizer, Institut Català de la Salut, [Martin-Broto J, Hindi N] Medical Oncology Department, University Hospital Virgen del Rocio, Sevilla, Spain. Institute of Biomedicine of Sevilla (IBIS, HUVR, CSIC, Universidad de Sevilla), Sevilla, Spain. [Grignani G] Division of Medical Oncology, Candiolo Cancer Institute, FPO - IRCCS - Str. Prov.le 142, km. 3,95 - Candiolo (TO) 10060, Candiolo, Italy. [Martinez-Trufero J] Medical Oncology Department, Miguel Servet University Hospital, Zaragoza, Spain. [Redondo A] Department of Medical Oncology, Hospital Universitario La Paz, Madrid, Spain. [Valverde C] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Journal for ImmunoTherapy of Cancer
r-IIB SANT PAU: Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Digital.CSIC. Repositorio Institucional del CSIC
Scientia
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)

مصطلحات موضوعية: Male, 0301 basic medicine, Oncology, Cancer Research, sarcoma, Antineoplastic Agents, Immunological, 0302 clinical medicine, Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents::Antineoplastic Agents, Immunological [CHEMICALS AND DRUGS], Sunitinib, Clinical endpoint, Immunology and Allergy, RC254-282, Clinical/Translational Cancer Immunotherapy, Neoplasms::Neoplasms by Histologic Type::Neoplasms, Connective and Soft Tissue::Sarcoma [DISEASES], clinical trials as topic, immunotherapy, translational medical research, Adult, Aged, Female, Humans, Middle Aged, Nivolumab, Sarcoma, Young Adult, Soft tissue sarcoma, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Immunological, Response Evaluation Criteria in Solid Tumors, 030220 oncology & carcinogenesis, Molecular Medicine, neoplasias::neoplasias por tipo histológico::neoplasias de tejido conjuntivo y de tejidos blandos::sarcoma [ENFERMEDADES], medicine.drug, medicine.medical_specialty, Combination therapy, Immunology, Antineoplastic Agents, Neutropenia, 03 medical and health sciences, Internal medicine, medicine, Sarcoma - Tractament, Survival rate, Pharmacology, business.industry, medicine.disease, 030104 developmental biology, Càncer - Immunoteràpia, business, acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos::inmunoterapia antineoplásica [COMPUESTOS QUÍMICOS Y DROGAS]

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::182dc458c4f701267e769974d8b3d7fc
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=1448